Menimbang Strategi Penatalaksanaan Deep Vein Thrombosis pada Pasien Strok Hemoragik

Raymond R. Tjandrawinata

doi:10.56951/nca87c96

Menimbang Strategi Penatalaksanaan Deep Vein Thrombosis pada Pasien Strok Hemoragik

Penulis

Raymond R. Tjandrawinata Molecular Pharmacologist, Center for Pharmaceutical and Nutraceutical Research and Policy, Universitas Katolik Indonesia Atma Jaya, Jakarta, Indonesia

DOI:

https://doi.org/10.56951/nca87c96

Editorial

Strok hemoragik merupakan kondisi akut dengan tingkat morbiditas dan mortalitas yang tinggi, dan sering disertai komplikasi berupa trombosis vena dalam (deep vein thrombosis/DVT). Dilema utama dalam tata laksana DVT pada kondisi ini adalah paradoks terapeutik, di mana penggunaan antikoagulan efektif mencegah embolisme paru, namun berisiko memperburuk perdarahan otak. Pedoman internasional merekomendasikan profilaksis mekanis seperti intermittent pneumatic compression (IPC) serta penggunaan antikoagulan dosis rendah pada hematoma yang stabil, meskipun bukti klinis masih terbatas. Alternatif biologis, seperti DLBS1033 yang berasal dari Lumbricus rubellus, menunjukkan potensi
keamanan dan efikasi pada laporan kasus di Indonesia. Perspektif etika, kebijakan kesehatan, serta inovasi farmakologis dan teknologi kecerdasan buatan sangat diperlukan untuk menciptakan strategi yang adaptif, adil, dan berbasis bukti dalam penatalaksanaan DVT pascastrok hemoragik.

Unduhan

Baca Selengkapnya

Referensi

1. Amin AN, Lin J, Thompson S, Wiederkehr D. Rate of deep-vein thrombosis and pulmonary embolism during the care continuum in patients with acute ischemic stroke in the United States. BMC Neurol. 2013;13(1):17. doi:10.1186/1471-2377-13-17.

2. CLOTS Trials Collaboration. Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial. Lancet 2013;382(9891):516–24. doi:10.1016/S0140-6736(13)61050-8.

3. Greenberg SM, Ziai WC, Cordonnier C, Dowlatshahi D, Francis B, Goldstein JN, et al. 2022 Guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association/American Stroke Association. Stroke 2022;53(7):e282–361. doi:10.1161/STR.0000000000000407.

4. Kappelle LJ. Preventing deep vein thrombosis after stroke: strategies and recommendations. Curr Treat Options Neurol. 2011;13(6):629–35. doi:10.1007/s11940-011-0147-4.

5. Liu L, Zheng H, Wang DZ, Wang Y, Hussain M, Sun H, et al. Risk assessment of deep-vein thrombosis after acute stroke: a prospective study using clinical factors. CNS Neurosci Ther. 2014;20(5):403–10. doi:10.1111/cns.12227.

6. National Institute for Health and Care Excellence (NICE). Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. NICE guideline NG89. London: NICE; 2018 [cited 2025 Sep 15]. Available from: https://www.nice.org.uk/guidance/ng89/resources/venous-thromboembolism-in-over-16s-reducing-the-risk-of-hospitalacquired-deep-vein-thrombosis-orpulmonary-embolism-pdf-1837703092165 cited Sep 15th, 2025.

7. Prabhakaran S, Herbers P, Khoury J, Adeoye O, Khatri P, Ferioli S, et al. Is prophylactic anticoagulation for deep venous thrombosis common practice after intracerebral hemorrhage? Stroke. 2015;46(2):369–75. doi:10.1161/STROKEAHA.114.008006.

8. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62. doi:10.1016/S0140-6736(13)62343-0.

9. Shoamanesh A, Klijn CJ, Sheth KN, Veltkamp R, Sandset EC, Cordonnier C, et al. Oral anticoagulation following intracranial haemorrhage in patients with atrial fibrillation. Eur Stroke J. 2025;10(1 Suppl):35–45. doi:10.1177/23969873241296803.

10. Tjandrawinata R. Jejak bioetika: teori, kasus, dan kebijakan di era kontemporer. 1st ed. Jakarta: Dexomics; 2024.